Massive Bio, an AI-driven biotechnology-focused startup, received an investment of USD 16.5 million in a Series A funding round led by Revo Capital, one of Türkiye's largest VCs.
Founded in 2015 by Dr. Selin Kurnaz, Çağatay Çulcuoğlu, and Dr. Arturo Loaiza-Bonilla, Massive Bio is the only AI-driven platform that connects bio-pharmaceutical clinical trials with cancer patients regardless of location and socioeconomic background within hours using AI technology and big data.
The new funding brings the company's total investment to USD 23.3 million. According to Selin Kurnaz, Massive Bio is a scaleup rather than a startup. “Our growth has been fueled significantly by increased demand from pharmaceutical companies and a USD 16.5 million new funding in 2022," Kurnaz added.
Massive Bio boasts 26 pharma clients with 9,200 clinical trials open across over 1,000 sites in 12 countries. The recent investment will enable the company to further accelerate its multi-country expansion plans.